Quanterix to Showcase Expertise at Leading Industry Conferences

Scientists will lead sessions on vital research findings and ongoing studies related to its ultra-sensitive single-molecule digital immunoassay (Simoa) technology

LEXINGTON, Mass.--()--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it will be presenting at The Alzheimer’s Association International Conference (AAIC), July 18-23, 2015 in Washington D.C., and The AACC Annual Meeting and Clinical Lab Expo, July 26 – 30, 2015 in Atlanta, Georgia. Quanterix scientists will be presenting research based on the Company’s Single Molecule Array technology, Simoa, which is capable of measuring individual proteins at concentrations 1,000 times lower than the best immunoassays available today.

Quanterix scientists will be presenting at the following times during AACC:

Poster Session— Fully automated ultrasensitive digital immunoassay for troponin using single molecule array technology
Wednesday, July 29, 2015 at 9:30 a.m. – 5:00 p.m.
Presented by Purvish Patel, Associate Scientist, Quanterix in Section B024 in Exhibit Hall B1

Poster Session— Fully automated digital immunoassay for p24 on the Simoa HD-1 Analyzer with the sensitivity of nucleic acid amplification for acute HIV infection
Wednesday, July 29, 2015 at 9:30 a.m. – 5:00 p.m.
Presented by Carlos Cabrera, Research Scientist, Quanterix in Section B073 in Exhibit Hall B1

Connect with Quanterix at AAIC:
To connect with Quanterix scientists at AAIC and learn more about their research and technology, please visit them at booth #511.

Connect with Quanterix at the AACC Annual Meeting and Clinical Lab Expo:
To connect with Quanterix scientists at AACC and learn more about their research and technology, please visit them at booth #4820.

To learn more about Simoa, please visit: http://www.quanterix.com/technology/simoa-science.

About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.

Contacts

PAN Communications
Nikki Festa & Caitlyn Keating, 617-502-4300
quanterix@pancomm.com

Release Summary

Scientists will lead sessions on vital research findings and ongoing studies related to its ultra-sensitive single-molecule digital immunoassay (Simoa) technology

Contacts

PAN Communications
Nikki Festa & Caitlyn Keating, 617-502-4300
quanterix@pancomm.com